(lp0
S"2 Reasons Behind Sarepta Therapeutics Inc.'s 6.9% February Jump Motley Fool - Mar 3, 2017 Sarepta also said that it ended the year with more than $329.3 million in cash on its books, which doesn't include the proceeds from the voucher sale.Vetr Advises Hold On Sarepta - Benzinga"
p1
aS"Sarepta Therapeutics Inc : Will Payors Reimburse Exondys 51? Smarter Analyst - Mar 10, 2017 Cowen analyst Ritu Baral is out with a new research note on shares of Sarepta Therapeutics Inc , as it appears that payors are still actively evaluating and reevaluating coverage of the company's muscular dystrophy drug Exondys 51.Payor Re-Evaluation On Exondys Positive For Sarepta - BenzingaSarepta  Exondys 51 Payor Discussions Progressing - Cowen - StreetInsider.com"
p2
aS'Sarepta Therapeutics Inc  Stock Heads Higher on Analyst Upgrade Investorplace.com - Mar 2, 2017 The Leerink Swann analysts say that the reason for the Sarepta Therapeutics Inc rating upgrade and increase in price target is because the stock appears to have fully consolidated and reflects reasonable expectations for the Exondys launch.Sarepta  Q4 Loss Widens; Sales of Duchenne Drug Slow - Yahoo FinanceSarepta Therapeutics, Inc. | $SRPT Stock | Shares Fall On Poor Fourth Quarter ... - TickerTV News '
p3
aS"Sarepta Therapeutics Inc Risk Points versus Health Care CML News - Mar 13, 2017 This is a scatter plot analysis of the critical risk points from the option market for Sarepta Therapeutics Inc  compared to its own past and the Health Care ETF.Sarepta Therapeutics Inc  Upgraded at Vetr Inc. - Chaffey BreezeAnalysts mean rating score stands at 1.90 while Sarepta Therapeutics, Inc.'s ... - Hot Stocks Point"
p4
aS'Oppenheimer Stays Bullish on Sarepta Therapeutics Inc  as the Stock ... Smarter Analyst - Feb 16, 2017 Oppenheimer analyst Hartaj Singh is out with a new research note on shares of Sarepta Therapeutics Inc , reiterating an Outperform rating and price target of $76.Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2016 Financial ... - Yahoo FinanceSarepta Therapeutics, Inc.  reported EPS of -1.18 on 12/31/2016 - TopChronicle'
p5
aS'Is a Surprise Coming for Sarepta Therapeutics  This Earnings Season? Yahoo Finance - Feb 27, 2017 Investors are always looking for stocks that are poised to beat at earnings season and Sarepta Therapeutics, Inc. SRPT may be one such company.'
p6
aS'Sarepta Therapeutics Agrees to Sale of Priority Review Voucher for $125M Yahoo Finance - Feb 21, 2017 Sarepta Therapeutics, Inc. , a commercial-stage developer of innovative RNA-targeted therapeutics, today announced it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher .Sarepta Sells Priority Review Voucher for $125M  - InvestopediaCommit To Purchase Sarepta Therapeutics At $18, Earn 16.7% Using Options - Nasdaq'
p7
aS'Apache, Sarepta Therapeutics, Seaspan Times of India - Mar 2, 2017 HIGHLIGHTS * Apache Corp : Barclays cuts to underweight from equal weight * Sarepta Therapeutics Inc : Leerink raises to outperform from market Perform * Seaspan Corp : JP Morgan raises to neutral from underweight Following is a summary of research&nbsp;...'
p8
aS"Analysts Wary on Valeant Pharmaceuticals Intl Inc  as Salespeople Flee ... Smarter Analyst - Feb 24, 2017 Wells Fargo and Needham are chiming in with mixed takes on biotech companies Valeant Pharmaceuticals Intl Inc  and Sarepta Therapeutics Inc . One analyst is investigating rumblings that over 50 of Valeant's GI salespeople&nbsp;..."
p9
aS'Sarepta -2% after Q4 results Seeking Alpha - Feb 28, 2017 Q4 non-GAAP net loss of $38.7M or $0.71 per share vs. loss of $58.3M and $1.30 one year ago. Revenue of $5.4M recognized for EXONDYS 51 in Q4.'
p10
a.